You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR ACETAMINOPHEN; IBUPROFEN SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ACETAMINOPHEN; IBUPROFEN SODIUM

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00261586 ↗ A Safety Trial to Compare Different Analgesics in Combination With Low Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach Completed Johnson & Johnson Consumer and Personal Products Worldwide Phase 4 1969-12-31 The purpose of this study is to compare several analgesics given in approved daily doses in combination with a daily cardioprotective dose of aspirin (81 mg), to study their bleeding properties and their effects on the stomach in healthy volunteers.
NCT00525993 ↗ Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols Unknown status Merck Sharp & Dohme Corp. Phase 4 2008-12-01 The investigators will study 2 doses of etoricoxib to prove that 60 mg once daily will be non-inferior to etoricoxib 90mg daily (for 14 days) in the treatment of acute ankle sprain in sports. The investigators objective is to discuss the point that the investigators will follow the minimal dose that is effective for the treatment of this acute condition in orthopedic.
NCT00525993 ↗ Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols Unknown status Núcleo de Estudos em Esportes e Ortopedia, Brazil Phase 4 2008-12-01 The investigators will study 2 doses of etoricoxib to prove that 60 mg once daily will be non-inferior to etoricoxib 90mg daily (for 14 days) in the treatment of acute ankle sprain in sports. The investigators objective is to discuss the point that the investigators will follow the minimal dose that is effective for the treatment of this acute condition in orthopedic.
NCT01080677 ↗ Caffeine/Propranolol Intervention for Acute Migraine Completed Stanford University Phase 2 2007-01-01 This is a research study to assess the safety of caffeine/propranolol at different dose levels. We want to find out what effects, good and/or bad, it has on patients and their migraines.
NCT02017197 ↗ Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil Completed Fundação de Amparo à Pesquisa do Estado de São Paulo Phase 4 2014-08-01 The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗ Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil Completed Federal University of São Paulo Phase 4 2014-08-01 The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02021474 ↗ A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis Unknown status AgoneX Biopharmaceuticals, Inc. Phase 2 2015-09-01 This is a prospective multi-center, randomized, double-blind, two treatment period, placebo-controlled study in subjects with migraine headache requiring prophylactic treatment. The patients will be randomized to receive either histamine dihydrochloride sc or placebo (matching vehicle only) sc for 16 weeks. The safety and efficacy outcome measures will be assessed at selected dosing segments during the 16 week treatment phase and 4 weeks (week 20), 8 weeks (week 24) after the last Injection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ACETAMINOPHEN; IBUPROFEN SODIUM

Condition Name

Condition Name for ACETAMINOPHEN; IBUPROFEN SODIUM
Intervention Trials
Sprains and Strains 1
Analgesics 1
Atrial Fibrillation 1
Cerebral Palsy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ACETAMINOPHEN; IBUPROFEN SODIUM
Intervention Trials
Migraine Disorders 2
Pain, Postoperative 1
Atrial Fibrillation 1
Hip Dislocation, Congenital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ACETAMINOPHEN; IBUPROFEN SODIUM

Trials by Country

Trials by Country for ACETAMINOPHEN; IBUPROFEN SODIUM
Location Trials
United States 4
Brazil 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ACETAMINOPHEN; IBUPROFEN SODIUM
Location Trials
California 2
Illinois 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ACETAMINOPHEN; IBUPROFEN SODIUM

Clinical Trial Phase

Clinical Trial Phase for ACETAMINOPHEN; IBUPROFEN SODIUM
Clinical Trial Phase Trials
Phase 4 4
Phase 2 2
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ACETAMINOPHEN; IBUPROFEN SODIUM
Clinical Trial Phase Trials
Completed 4
Unknown status 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ACETAMINOPHEN; IBUPROFEN SODIUM

Sponsor Name

Sponsor Name for ACETAMINOPHEN; IBUPROFEN SODIUM
Sponsor Trials
Stanford University 1
Fundação de Amparo à Pesquisa do Estado de São Paulo 1
Federal University of São Paulo 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ACETAMINOPHEN; IBUPROFEN SODIUM
Sponsor Trials
Other 8
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.